PL2608802T3 - Immunoterapeutyczny sposób leczenia raka gruczołu krokowego - Google Patents

Immunoterapeutyczny sposób leczenia raka gruczołu krokowego

Info

Publication number
PL2608802T3
PL2608802T3 PL11751668T PL11751668T PL2608802T3 PL 2608802 T3 PL2608802 T3 PL 2608802T3 PL 11751668 T PL11751668 T PL 11751668T PL 11751668 T PL11751668 T PL 11751668T PL 2608802 T3 PL2608802 T3 PL 2608802T3
Authority
PL
Poland
Prior art keywords
prostate cancer
treating prostate
immunotherapeutic method
immunotherapeutic
treating
Prior art date
Application number
PL11751668T
Other languages
English (en)
Inventor
Bennink Herman Jan Tijmen Coelingh
Original Assignee
Pantarhei Bioscience B.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pantarhei Bioscience B.V. filed Critical Pantarhei Bioscience B.V.
Publication of PL2608802T3 publication Critical patent/PL2608802T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/884—Vaccine for a specifically defined cancer prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL11751668T 2010-08-27 2011-08-29 Immunoterapeutyczny sposób leczenia raka gruczołu krokowego PL2608802T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP10174349 2010-08-27
EP11751668.2A EP2608802B1 (en) 2010-08-27 2011-08-29 Immunotherapeutic method for treating prostate cancer

Publications (1)

Publication Number Publication Date
PL2608802T3 true PL2608802T3 (pl) 2017-08-31

Family

ID=44543718

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11751668T PL2608802T3 (pl) 2010-08-27 2011-08-29 Immunoterapeutyczny sposób leczenia raka gruczołu krokowego

Country Status (9)

Country Link
US (1) US9295720B2 (pl)
EP (1) EP2608802B1 (pl)
CN (1) CN103179977B (pl)
BR (1) BR112013004389A2 (pl)
CA (1) CA2809153C (pl)
ES (1) ES2621806T3 (pl)
PL (1) PL2608802T3 (pl)
RU (1) RU2586774C2 (pl)
WO (1) WO2012026820A2 (pl)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016080830A2 (en) * 2014-11-18 2016-05-26 Pantarhei Bioscience B.V. Immunotherapeutic method for treating pancreatic cancer
CN111511392A (zh) * 2017-10-31 2020-08-07 潘塔希生物科学股份有限公司 用于治疗和/或预防肺癌的免疫治疗方法
WO2021133036A1 (ko) 2019-12-23 2021-07-01 주식회사 엘지화학 항-lilrb1 항체 및 그의 용도
US20250026818A1 (en) 2021-10-19 2025-01-23 Sciencemed Spóka z ograniczon odpowiedzialnoci Male contraception
CN117567633B (zh) * 2023-11-27 2025-10-24 福州迈新生物技术开发有限公司 抗p504s蛋白单克隆抗体及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5328470A (en) 1989-03-31 1994-07-12 The Regents Of The University Of Michigan Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
US5641487A (en) * 1989-06-12 1997-06-24 The Government Of The United States Of America As Represented By The Secretary Department Of Health And Human Services Contraceptive vaccine based on alloimmunization with zona pellucida polypeptides
US5272070A (en) 1991-03-08 1993-12-21 Board Of Regents, The University Of Texas System Method for the preparation of cell lines producing Man3 GlcNac 2 asparagine-linked gylcans and cell lines produced thereby
US5789543A (en) 1993-12-30 1998-08-04 President And Fellows Of Harvard College Vertebrate embryonic pattern-inducing proteins and uses related thereto
EP1056858B1 (en) 1998-02-19 2004-12-08 Eastern Virginia Medical School RECOMBINANT ACTIVE HUMAN ZONA PELLUCIDA PROTEIN 3 (hZP3)
FR2777890B1 (fr) 1998-04-22 2000-12-29 Roussy Inst Gustave Composes peptidiques d'hsp70 utiles dans l'immunotherapie du cancer
ES2330017T3 (es) 1998-05-23 2009-12-03 Leiden University Medical Center Ligandos de cd40 y peptidos de ctl para tratar tumores.
ES2253851T3 (es) 1998-08-07 2006-06-01 Curis, Inc. Composicion farmaceutica estable de proteinas hedgehog y uso de la misma.
US6455041B1 (en) * 1998-11-17 2002-09-24 Bonita S. Dunbar Immunogenic epitopes of the human zona pellucida protein (ZP1)
US6359196B1 (en) 1999-09-23 2002-03-19 Finn Lok Germination-specific plant promoters
ES2299473T3 (es) 2000-01-31 2008-06-01 Pharming Intellectual Property B.V. Inhibidor de c1 humano producido en la leche de mamiferos transgenicos.
WO2002012330A2 (en) * 2000-08-04 2002-02-14 Zymogenetics, Inc. Human secreted protein, zzp1
AU2002219711B8 (en) 2000-12-08 2006-03-02 Academisch Ziekenhuis Leiden Long peptides of 22-45 amino acid residues that induce and/or enhance antigen specific immune responses
EP2301972A1 (en) * 2002-08-12 2011-03-30 The Council Of The Queensland Institute Of Medical Research Method to prepare immunogenic lipopeptides comprising T-helper and B-cell epitopes
PT1618128E (pt) 2003-04-23 2010-10-13 Max Planck Gesellschaft Vacina de tuberculose com eficácia melhorada
TWI329130B (en) 2003-06-19 2010-08-21 Bestewil Holding Bv Functionally reconstituted viral membranes containing adjuvant
WO2007058536A1 (en) * 2005-11-16 2007-05-24 Pantarhei Bioscience B.V. Pharmaceutical composition for treating or preventing ovarian cancer

Also Published As

Publication number Publication date
CN103179977B (zh) 2016-10-26
EP2608802A2 (en) 2013-07-03
ES2621806T3 (es) 2017-07-05
US9295720B2 (en) 2016-03-29
CA2809153A1 (en) 2012-03-01
WO2012026820A3 (en) 2012-06-21
RU2013113639A (ru) 2014-10-10
CN103179977A (zh) 2013-06-26
BR112013004389A2 (pt) 2016-05-17
RU2586774C2 (ru) 2016-06-10
US20130224233A1 (en) 2013-08-29
CA2809153C (en) 2023-09-26
EP2608802B1 (en) 2017-02-22
WO2012026820A2 (en) 2012-03-01

Similar Documents

Publication Publication Date Title
IL276362A (en) Cancer treatment methods
EP2734207A4 (en) NEW COMPOSITIONS AND METHOD FOR THE TREATMENT OF PROSTATE CANCER
PL2542585T3 (pl) Sposoby leczenia nowotworu jelita grubego
ZA201205004B (en) Methods for treating pancreatic cancer
ZA201207229B (en) Method for breast cancer recurrence prediction under endocrine treatment
EP2643001A4 (en) METHOD OF TREATING CANCER
SG10201500124VA (en) Methods and Compositions for Treating Cancer
IL228644A0 (en) Cancer treatment methods
ZA201304225B (en) Methods of treating cancer
IL225623A0 (en) Psoriasis treatment methods
IL254964A0 (en) A method for treating breast cancer
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
EP2640390A4 (en) METHODS OF TREATING CANCER
EP2533781A4 (en) METHOD FOR THE TREATMENT OF BLOOD CANCER
IL218230A0 (en) Method of treating cancer
PL2608802T3 (pl) Immunoterapeutyczny sposób leczenia raka gruczołu krokowego
GB201004304D0 (en) Biomarkers for prostate cancer
EP2560648A4 (en) METHOD OF TREATING PANCREATIC CANCER
EP2593100A4 (en) METHOD OF TREATING REFRACTORY CANCER
EP2560639A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
EP2932273A4 (en) METHODS OF DIAGNOSING AND TREATING PROSTATE CANCER
WO2012106368A9 (en) Methods for inhibiting prostate cancer
PT2509599E (pt) Processo para o tratamento de cancro pancreático
EP2538944A4 (en) METHOD FOR TREATING BRAIN TUMORS
PT2560638E (pt) Método de tratamento de cancro gástrico